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ORIGINAL ARTICLE

Assessing cerebral glucose metabolism in patients with
idiopathic rapid eye movement sleep behavior disorder
Jingjie Ge1,4, Ping Wu1,4, Shichun Peng2, Huan Yu3, Huiwei Zhang1, Yihui Guan1, David Eidelberg2, Chuantao Zuo1, Yilong Ma2,5 and
Jian Wang3,5
Idiopathic rapid eye movement sleep behavior disorder (RBD) is a risk marker for subsequent development of neurodegenerative
parkinsonism. In this study, we aimed to investigate whether regional cerebral metabolism is altered in patients with RBD and
whether regional metabolic activities are associated with clinical measurements in individual patients. Twenty-one patients with
polysomnogram-conﬁrmed RBD and 21 age-matched healthy controls were recruited to undertake positron emission tomography
imaging with [18F]ﬂuorodeoxyglucose. Differences in normalized regional metabolism and correlations between metabolic activity
and clinical indices in RBD patients were evaluated on a voxel basis using statistic parametric mapping analysis. Compared with
controls, patients with RBD showed increased metabolism in the hippocampus/parahippocampus, cingulate, supplementary motor
area, and pons, but decreased metabolism in the occipital cortex/lingual gyrus (Po 0.001). RBD duration correlated with
metabolism positively in the anterior vermis (r = 0.55, P = 0.01), but negatively in the medial frontal gyrus (r = − 0.59, P = 0.005).
In addition, chin electromyographic activity presented a positive metabolic correlation in the hippocampus/parahippocampus
(r = 0.48, P = 0.02), but a negative metabolic correlation in the posterior cingulate (r = − 0.61, P = 0.002). This study has suggested
that region-speciﬁc metabolic abnormalities exist in RBD patients and regional metabolic activities are associated with clinical
measures such as RBD duration and chin electromyographic activity.
Journal of Cerebral Blood Flow & Metabolism (2015) 35, 2062–2069; doi:10.1038/jcbfm.2015.173; published online 29 July 2015
Keywords: 18F-ﬂuorodeoxyglucose; Parkinson’s disease; positron emission tomography; rapid eye movement sleep behavior
disorder; statistic parametric mapping analysis

INTRODUCTION
Idiopathic rapid eye movement sleep behavior disorder (RBD) is a
parasomnia characterized by the loss of normal skeletal muscle
atonia during rapid eye movement (REM) sleep with prominent
motor activity and dreaming. Patients with RBD are at substantial
risk for the future development of neurodegenerative disorders,
particularly synucleinopathies such as Parkinson’s disease (PD),
dementia with Lewy bodies (DLB), and multiple system atrophy.1–4
Imaging studies with single photon emission computed tomography (SPECT) and positron emission tomography (PET) have
attempted to detect abnormal functional alterations in RBD
patients predictive of evolution toward the onset of synucleinopathies. Reduced striatal binding of radioligands such as
123
I-FP-CIT and 11C-DTBZ was reported to reveal subclinical

nigrostriatal dopaminergic damage in RBD patients before the
appearance of PD.5–8 Cerebral blood ﬂow (CBF) studies with
SPECT also showed some similarities in the distribution of
impaired brain perfusion between patients with RBD and those
with synucleinopathies as a consequence of localized neural
degeneration.9–11
18
F-ﬂuorodeoxyglucose (FDG) PET has been a valuable imaging
method for studying neurodegenerative disorders in the past two
decades. Differences in regional metabolic activity could be
measured between parkinsonian patients and healthy subjects by
using a voxel-to-voxel search.12–14 By contrast, network analysis of
FDG PET images was useful in discerning abnormal functional
connectivity in PD and atypical parkinsonism.15–17 These complementary techniques have proved to be useful in describing the
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physiopathology of synucleinopathy disorders at both the local
and system levels, and therefore provide speciﬁc biomarkers in
the assessment of disease progression, modiﬁcation, and treatment response.18
FDG PET has also been extended to detect abnormalities in the
prodromal stage of synucleinopathies and to predict potential
phenoconversion toward subsequent development of a neurodegenerative disease. Indeed, a recent investigation reported
regional differences in metabolic activity at the major nodes (i.e.
pons and putamen) of a PD-related covariance pattern in RBD
patients.10 Of importance, our research group has just identiﬁed a
spatial covariance pattern in patients with RBD by using the
network analysis of FDG PET images from a cohort of RBD patients
and healthy controls.19 Although this pattern was designed to
reveal RBD-related metabolic alteration at a system level, it did not
provide valuable information concerning metabolic differences
and clinical correlates in speciﬁc cerebral regions. In the current
study, we aimed to map such areas in the same set of FDG PET
images by using voxel-to-voxel searches on a whole-brain basis.
Furthermore, we explored the relationships between clinical
indices and relative metabolic values on a voxel basis.

cannula and mouth thermocouple. Thoracoabdominal movement was
measured by inductance plethysmogram, and arterial oxygen saturation
(SpO2) by ﬁnger pulse oximetry. Sleep stage was manually scored
according to the standard criteria,22 with the exception that REM sleep
was scored on the basis of electroencephalograph and electrooculogram
only. During REM sleep, the presence of phasic submental EMG activity
(415%) and/or tonic EMG activity (430%) was used to determine REM
sleep without atonia stage.22 The PSG parameters for this RBD cohort have
been published previously.19

MATERIALS AND METHODS
Subjects

Image Processing

FDG PET Scanning
All subjects were asked to fast for at least 6 h, but had free access to water
before PET imaging. PET scans were performed with a Siemens Biograph
64 PET/CT (Siemens, Munich, Germany) in a three-dimensional mode. A
computed tomography transmission scan was ﬁrst performed for
attenuation correction. The emission scan was acquired between 45 and
55 minutes after intravenous injection of 185 MBq of 18F-FDG. As no arterial
blood sampling was taken in this clinical imaging protocol, we used
radioactivity images to measure changes in relative regional glucose
metabolism. All studies in patients and normal individuals were performed
in a resting state in a quiet and dimly lit room. All patients and normal
individuals were monitored via cameras and remained awake during the
course of uptake and scanning procedure.

Imaging data were processed by using Statistical Parametric Mapping
(SPM5) software (Wellcome Department of Imaging Neuroscience, Institute
of Neurology, London, UK) implemented in Matlab 7.4.0 (Mathworks,
Sherborn, MA, USA). Scans from each subject were spatially normalized
into Montreal Neurological Institute (MNI) brain space with linear and
nonlinear three-dimensional transformations. The normalized PET images
were then smoothened by a Gaussian ﬁlter of 10 mm full-width at halfmaximum over a three-dimensional space to increase signal-to-noise ratio
for statistic analysis. The set of resulting images in both RBD and healthy
subjects described above had previously been used for identifying the
RBD-related brain network.19

Twenty-one RBD patients (male/female 17:4; age 65.0 ± 5.6 (mean ± s.d.)
years) were recruited in this study from 38 patients who were sequentially
diagnosed with RBD at the Sleep and Wake Disorders Center, Department
of Neurology, Huashan Hospital, Shanghai, China. The others were
excluded because of their unwillingness to undertake FDG PET. Mean
RBD duration of the enrolled patients was 5.7 ± 3.5 years at the time of PET
scanning. All patients participating in this study met the RBD diagnostic
criteria of the Second edition of the International Classiﬁcation of Sleep
Disorders: (1) Presence of REM sleep without atonia on polysomnography
(PSG) during REM stage. (2) At least one of the following is present: (a)
sleep-related injurious or disruptive behaviors by history and (b) abnormal
REM sleep behaviors documented during PSG monitoring. (3) Absence of
electroencephalograph epileptiform activity during REM sleep unless RBD
can be clearly distinguished from any concurrent REM sleep-related seizure
disorder. (4) The sleep disturbance is not better explained by another sleep
disorder, medical or neurologic disorders, mental disorders, medication
use, or substance use disorder.
To rule out neurologic conditions, all patients underwent a standard
neurologic examination followed by a further test for parkinsonism by a
senior specialist of movement disorders. The Uniﬁed Parkinson’s Disease
Rating Scale motor rating (UPDRS III, items 18 to 31) was used as an index
of parkinsonian signs. These patients had no evident parkinsonism (UPDRS
motor score 2.4 ± 2.1; range 0 to 7) and took no psychotropic medications
including antidepressants and anxiolytics. All the patients exhibited normal
cognitive abilities for memory, language, executive, visuospatial functions,
and attention according to the commonly used clinical criteria based on
Mini-Mental State Examination score (28.7 ± 1.2; range 26 to 30).20
This study also included 21 healthy subjects who were age- and gendermatched to the patients with RBD (male/female 17:4; age 62.5 ± 7.5 years).
They had no history of neurologic or medical disorders and each had a
normal neurologic examination. These subjects did not undergo PSG, but
all tested negative by RBD Single-Question Screen.21
This study was approved by the Ethics Committee of Huashan Hospital
in Shanghai, China. The study was carried out in compliance with the Code
of Ethics of the World Medical Association and the standards established
by the author's Institutional Review Board and granting agencies. All
subjects or a legally responsible relative gave informed consent to take
part in the study before undergoing PET scanning.

PET imaging data were analyzed by using the SPM5 software as described
previously.23 To characterize metabolic activity in RBD patients compared
with controls, we performed a group comparison by using a two-sample
t-test according to the general linear model at each voxel. Mean signal
differences over the whole brain were removed by analysis of covariance
in each individual subject. We also used a multiple regression analysis to
determine the relationship between cerebral metabolic values and clinical
measures (i.e., RBD duration and chin EMG activity) in patients with RBD.
These two variables were entered as covariates into the model together
along with age and UPDRS scores to eliminate the interaction between
these factors.
To evaluate the results, we set the peak threshold at Po0.001
(uncorrected) over whole brain regions with an extent threshold of 60
voxels (corresponding to a tissue volume of 480 mm3). For a stricter criterion,
we also highlighted clusters that survived a family-wise error correction at
Po0.05. Signiﬁcant regions were localized by Talairach–Daemon software
(Research Imaging Center, University of Texas Health Science Center, San
Antonio, TX, USA). The SPM maps for altered glucose metabolism and
clinical correlations were overlaid on a standard T1-weighted magnetic
resonance imaging (MRI) brain template in stereotaxic space.
To quantify metabolic changes in speciﬁc regions, we used a 4-mm radius
spherical volume of interest (VOI) centered at the peak voxel of clusters that
were signiﬁcant in the SPM analyses. We then calculated the relative cerebral
glucose metabolic values (i.e., globally adjusted) in patients and normal
individuals with the ScanVP software (Version 5.9.1; Center for Neuroscience,
the Feinstein Institute for Medical Research, Manhasset, NY, USA).

Polysomnographic Evaluation

Statistic Analysis

All patients with RBD were conﬁrmed by overnight audio-video-PSG
recordings in our sleep laboratory. Measured PSG variables included the
following: electroencephalograph with six-channel scalp electroencephalograph montages (F3/F4, C3/ C4, O1/O2 referred to the contralateral
mastoid), electrooculography, and electromyography (EMG) (submental,
left lower limb, and right lower limb). Airﬂow was measured using a nasal

Differences in regional metabolic values between RBD patients and normal
controls were assessed by using two-sample t-tests. In addition, correlations between regional metabolic values and corresponding clinical indices
in RBD patients were assessed by computing Pearson's correlation
coefﬁcients. All analyses were performed using the SPSS software (SPSS,
Chicago, IL, USA) and considered signiﬁcant for Po0.05.

© 2015 ISCBFM
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RESULTS
Characteristics of Relative Brain Activity in Patients with RBD
In comparison with healthy controls, patients with RBD showed
increased metabolism bilaterally in the superior frontal gyrus,
supplementary motor area (SMA), cingulate (BA 24), hippocampus/parahippocampal gyrus, insula, inferior parietal lobule,
and the pons, and in the left superior temporal gyrus (BA 39), right
precuneus (BA 31), and right cerebellar tonsil, associated with
decreased metabolism in the bilateral occipital cortex and lingual
gyrus (BA 17, 18), right superior temporal gyrus (BA 22), and left
transverse temporal gyrus (BA 41) (Figure 1A and Table 1).
Figure 1B showed the differences in relative metabolic values
between the RBD and control groups in the four major functional
regions (Figure 1A). The increased metabolic values in the VOIs
centered at the right cingulate, left SMA, and right pons displayed
signiﬁcant group differences between patients and healthy
individuals (P o 0.001). Similarly, the decreased metabolic value
in the VOI centered at the left lingual gyrus also showed
signiﬁcant group discrimination between patients and controls
(P o 0.001).
Correlation of Clinical Indices with Relative Brain Activity in
Patients with RBD
The regression analysis yielded a positive correlation of RBD
duration in patients with metabolic activity in the left posterior
cingulate (BA 31), right precuneus (BA 7), and right anterior
vermis. In contrast, RBD duration correlated negatively with
metabolic activity in the bilateral frontal gyri, right anterior

cingulate (BA 32), left inferior temporal gyrus (BA 20), insula (BA
13), postcentral gyrus (BA 3), and right culmen (Figure 2A and
Table 2). The sample plots for the two major regions from the
regression analysis (see Figure 2A) were given in Figure 2B. The
duration in RBD patients correlated signiﬁcantly with relative
metabolic values in the right anterior vermis (r = 0.55, P = 0.01), as
well as in the right medial frontal gyrus (r = − 0.59, P = 0.005).
We also observed a positive correlation between phasic chin
EMG activity and metabolic activity in the bilateral parahippocampal gyrus, but negative correlations in the bilateral frontal
gyrus, right postcentral gyrus, left posterior cingulate (BA 23), and
temporal gyrus (BA 21, 39) (Figure 3A and Table 2). The sample
plots for the two corresponding regions (see Figure 3A) were
presented in Figure 3B. The phasic chin EMG activity in RBD
patients correlated signiﬁcantly with relative metabolic values in
the left parahippocampus (r = 0.48, P = 0.02), as well as in the left
posterior cingulate (r = − 0.61, P = 0.002).
DISCUSSION
This article describes the ﬁrst functional imaging study to map
changes in regional glucose metabolic activity on a whole-brain
basis in the same derivation cohort of PSG-conﬁrmed RBD patients
described previously.19 We found that RBD patients had abnormal
metabolic activity in both cortical and subcortical regions relative
to normal controls. The signiﬁcant group differences in these brain
regions were conﬁrmed by post hoc VOI analyses of relative
metabolic values. Multiple regression analysis in the patients
showed signiﬁcant correlations between regional metabolic

Figure 1. Brain regions with relative abnormal metabolism in patients with idiopathic rapid eye movement sleep behavior disorder (RBD).
(A) Normalized glucose metabolism in the RBD patients increased (red) bilaterally in the superior frontal gyrus, supplementary motor area
(SMA), cingulate, hippocampus/parahippocampal gyrus, precuneus/superior parietal lobule, and the pons, but decreased (blue) bilaterally in
the occipital cortex and lingual gyrus relative to the normal controls. The overlays are depicted in neurologic orientation. The gray-scale image
is a T1-weighted structural magnetic resonance imaging (MRI) that is representative of Montreal Neurological Institute (MNI) space. The
thresholds of the color bars represent T values. (B) Differences in regional glucose metabolism in the RBD patients and normal subjects
illustrated by post hoc values obtained within a spherical volume of interest (VOI) (4-mm radius) with the center coordinates of each VOI given
in the parentheses on each panel. The graphs showed relative metabolic increases in the right cingulate, left SMA, and right pons, but
decrease in the left lingual gyrus. The error bars represent s.e.m.
Journal of Cerebral Blood Flow & Metabolism (2015), 2062 – 2069
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Table 1.

Brain regions with signiﬁcant metabolic differences in idiopathic RBD patients compared with normal subjects

Structure

Brodmann area

MNI coordinatesa

Hemisphere
X

Y

Z

ZMax

Cluster size (mm3)

1,472
1,232
69,000

b

Increased metabolism
Superior frontal gyrus
Superior frontal gyrus
Parahippocampal gyrus (hippocampus)c
Cingulate gyrus
Cingulate gyrus (supp_motor_area)c
Cingulate gyrusc
Insula
Insula
Superior temporal gyrus
Inferior parietal lobule
Inferior parietal lobule
Precuneus
Culmen (pons)c
Cerebellar tonsil
Decreased metabolismb
Occipital cortex/lingual gyrusc
Occipital cortex/lingual gyrus
Superior temporal gyrus
Transverse temporal gyrus

11
11
35
24
32
24
13
13
39
40
40
31

Left
Right
Left
Left
Left
Right
Left
Right
Left
Left
Right
Right
Left
Right

− 22
28
− 28
− 16
− 12
16
− 38
40
− 34
− 54
52
20
− 10
32

62
64
− 14
4
16
−6
−6
−6
− 58
− 28
− 38
− 54
− 32
− 54

− 12
− 12
− 28
40
46
52
24
26
28
32
36
30
− 34
− 44

4.07
3.98
5.21
5.17
5.13
5.61
5.09
4.47
4.24
5.50
4.24
3.54
3.94
3.40

18
17
22
41

Left
Right
Right
Left

−4
10
68
− 46

− 86
− 92
− 34
− 30

−2
−6
16
10

6.61
6.16
4.85
3.84

61,960
3,408
2,336
528
2,504
2,400
880
3,888
592
72,920
1,320
608

FWE, family-wise error; MNI, Montreal Neurological Institute; RBD, rapid eye movement sleep behavior disorder. aMNI standard space. bSurvived at uncorrected
Po0.001, KE = 60 voxels. cSurvived at FWE P o0.05.

Figure 2. Brain regions correlated with duration in idiopathic rapid eye movement sleep behavior disorder (RBD) patients. (A) Regions with
positive correlation (red) were observed in the right anterior vermis, whereas those with negative correlation (blue) were found in the right
frontal gyrus and right anterior cingulate. The overlays are depicted in neurologic orientation. The gray-scale image is a T1-weighted structural
magnetic resonance imaging (MRI) that is representative of Montreal Neurological Institute (MNI) space. The thresholds of the color bars
represent T values. (B) Correlation between relative metabolic values and RBD duration in the right anterior vermis and right medial frontal
gyrus. The metabolic values were obtained post hoc within a spherical volume of interest (VOI) (4-mm radius) with the center coordinates of
each VOI given in the parentheses on each panel.

values and individual clinical indices such as RBD duration and
chin EMG activities. These results further showed the potential of
FDG PET in the assessment of disease progression and subsequent
evolution on a regional basis.
Metabolic Differences Between RBD Patients and Healthy Subjects
The principal ﬁnding of this study is the localization of diseaserelated metabolic abnormalities in RBD patients compared with
normal controls. The regions of abnormal metabolism seen in our
study were in accordance with the prominent areas reported
in other functional imaging studies. Pons and hippocampal gyrus,
for example, were observed consistently with elevated CBF by
using perfusion SPECT,11 particularly in the RBD patients who
© 2015 ISCBFM

subsequently developed PD and DLB.24 Altered microstructures,
volumes, and densities of the brainstem and/or hippocampus,
as well as thinning in cortical thickness, were also described in
MRI studies using diffusion tensor imaging and voxel-based
morphometry.25–28 As neurons in the subcoeruleus areas of the
brainstem have proved to be responsible for REM sleep atonia in
patients with RBD, it is not unexpected that pontine dysfunction
was observed in both the current and the previous imaging
studies.
Although we found no changes of putamen activity in the
current study, previous studies described increased CBF or glucose
metabolism in this region.10,11 Additionally, altered nigrostriatal
connectivity was observed in RBD patients by using resting-state
functional MRI.29 One possible reason for the absence of
Journal of Cerebral Blood Flow & Metabolism (2015), 2062 – 2069

Abnormal metabolic characteristics in RBD
J Ge et al

2066
Table 2.

Brain regions with signiﬁcant clinical correlation in idiopathic RBD patients using multivariate regression

Structure

Duration
Positiveb
Posterior cingulate gyrus
Precuneus
Anterior vermis
Negativeb
Superior frontal gyrus
Medial frontal gyrus
Medial frontal gyrus
Middle frontal gyrus
Middle frontal gyrus
Inferior frontal gyrus
Inferior frontal gyrus
Anterior cingulate gyrus
Inferior temporal gyrus
Insula
Postcentral gyrus
Culmen
Phasic chin EMG activity
Positiveb
Parahippocampal gyrus
Parahippocampal gyrus
Negativeb
Superior frontal gyrus
Superior frontal gyrus
Medial frontal gyrusc
Medial frontal gyrus
Postcentral gyrus
Posterior cingulate gyrus
Superior temporal gyrus
Middle temporal gyrus

Brodmann area

MNI coordinatesa

Hemisphere
X

Y

Z

ZMax

Cluster size (mm3)

31
7

Left
Right
Right

− 18
16
6

− 52
− 78
− 42

26
34
− 30

3.15
3.24
3.73

1136
936
2232

11
10
9
8
6
9
47
32
20
13
3

Right
Left
Right
Left
Right
Left
Right
Right
Left
Left
Left
Right

16
−6
2
− 30
32
− 38
32
6
− 52
− 36
− 32
8

58
50
52
30
12
4
28
28
− 52
28
− 24
− 46

− 12
−2
44
48
58
34
− 16
36
− 20
18
46
2

3.60
3.61
3.36
3.25
3.71
3.18
3.26
2.80
3.38
3.22
3.66
4.18

2952
1040
1272
1400
2696
848
1128
3760
3112
1064
1720
3816

35
35

Left
Right

− 16
20

− 22
− 22

− 20
− 18

3.61
3.6

1448
904

8
8
10
9
2
23
39
21

Left
Right
Left
Right
Right
Left
Left
Left

− 30
20
−8
18
54
−8
− 46
− 66

26
32
52
44
− 28
− 46
− 56
− 40

58
56
6
20
38
26
22
− 10

3.29
3.37
4.96
4.14
3.6
3.51
3.5
3.51

2064
864
3944
1520
2184
2904
3328
2344

FWE, family-wise error; MNI, Montreal Neurological Institute; RBD, rapid eye movement sleep behavior disorder. aMNI standard space. bSurvived at uncorrected
Po0.001. cSurvived at FWE Po 0.05.

Figure 3. Brain regions correlated with phasic chin electromyography (EMG) activity in idiopathic rapid eye movement sleep behavior disorder
(RBD) patients. (A) Regions with positive correlation (red) were observed bilaterally in the parahippocampal gyrus, whereas those with
negative correlations (blue) were found in the right frontal gyrus, right postcentral gyrus, left posterior cingulate, and left superior temporal
gyrus. The overlays are depicted in neurologic orientation. The gray-scale image is a T1-weighted structural magnetic resonance imaging (MRI)
that is representative of Montreal Neurological Institute (MNI) space. The thresholds of the color bars represent T values. (B) Correlation
between relative metabolic values and phasic chin EMG activity in the left parahippocampus and left posterior cingulate. The metabolic values
were obtained post hoc within a spherical volume of interest (VOI) (4-mm radius) with the center coordinates of each VOI given in the
parentheses on each panel.

metabolic alteration in the putamen in this study might be the
relative short RBD duration of our recruited patients. As the
putamen is commonly recognized to be associated with motor
dysfunction (e.g., limb tremor) in clinical parkinsonism, our result
Journal of Cerebral Blood Flow & Metabolism (2015), 2062 – 2069

may simply suggest that these patients are in the mild stage of
RBD. However, whether metabolic abnormalities of the putamen
exist in advanced RBD patients before phenoconversion to
parkinsonism remains to be determined by longitudinal studies.
© 2015 ISCBFM
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The current study also revealed some new areas with abnormal
metabolic activity in the cortex. The metabolic activity increased in
the SMA, cingulate, and superior frontal gyrus along with the
insula and inferior parietal lobe, but decreased in the occipital
cortex, lingual gyrus, and temporal gyrus. The increased perfusion
in the SMA was also reported during an RBD episode in a patient
by SPECT imaging,30 and these results further suggest that
elevated locomotor drive may be behind the clinical manifestation
of human RBD.1 Of note, the increased perfusion in the cingulate
seen in the RBD patients at baseline was previously found to be
predictive of eventual phenoconversion to PD.24 Conversely, the
reduced metabolic activity evident in the occipitotemporal
regions might be related to impaired color vision based on a
regional perfusion study.11 The different observations between the present study and the existing metabolic or perfusion
studies might be explained by the methodological factors
described below.
It may be worth considering the possible role of compensation
in RBD-related brain network. The controlling of normal muscle
atonia during REM sleep involves a speciﬁc circuitry that originally
projects from sublaterodorsal tegmental nucleus within the
brainstem. It has been proven that descending neurons from
sublaterodorsal tegmental nucleus has an important role in
inhibiting skeletal motoneurons, and therefore prevents the
occurrence of abnormal motor behavior during REM sleep; RBD
pathogenesis is likely to stem from the breakdown of this
circuitry.31 The relative hypermetabolism observed in RBD patients
in the pons and the wide range of neocortex in this study
may represent the overactivity of descending projections
from sublaterodorsal tegmental nucleus as an early compensatory mechanism to regulate abnormal muscle atonia. It is
expected that this effect might become weaker with the
progression of RBD towards the onset of any particular form of
synucleinopathies.
Correlation Between Regional Metabolism and Clinical Features
One unique feature of this study is that we delineated the cerebral
metabolic areas associated with RBD duration and phasic chin
EMG activity in RBD patients. Interestingly, the positive correlations of metabolic activity in the posterior cingulate gyrus with
RBD duration had been reproduced by those of corresponding
regional perfusion with deﬁcit in color vision.11 It is noteworthy
that a positive correlation was also observed between phasic
REM density and metabolic changes in the hippocampus/
parahippocampal region, a major area involved in the pathophysiology of RBD because of correlations observed between
its local perfusion and impaired motor, olfactory, and color
discrimination function.11,24 These ﬁndings in the cingulate
and hippocampal regions substantiated the involvement of
limbic circuits in support of RBD as a risk factor for cognitive
decline. Indeed, severity of REM atonia loss has been reported
to predict impending parkinsonism in RBD patients.32 In this
vein, elevated metabolic activity in the hippocampus/parahippocampus may be a harbinger of the neurodegenerative process in
RBD, leading to clinical parkinsonism, given that increased
baseline hippocampal perfusion points to the development of
presumed synucleinopathies.24 Nevertheless, the accuracy of this
prediction has to be further veriﬁed by follow-up studies in our
RBD sample.
Some other cerebral areas were also found to be in association
with each of these two clinical indices in this study, especially
those showing negative metabolic correlations in the frontal and
temporal cortices. The latter were generally compatible with the
decreased perfusion and corresponding cognitive correlations
described previously in patients with RBD.11 Although a multiple
regression design was applied to circumvent the interaction
between clinical factors in the analysis, we still observed an
© 2015 ISCBFM

overlap of cerebral regions correlating with these two indices (e.g.,
the frontal gyrus, postcentral gyrus, and temporal gyrus). One
potential explanation could be that, as excessive muscle activity
increased with RBD duration in patients,33 the resulting overlap
might arise from the synchronization of underlying pathophysiology between two clinical factors. Moreover, we found that the
metabolic values in the anterior and posterior aspects of cingulate
correlate negatively with RBD duration and chin EMG activity,
respectively. Why this relationship occurs is currently not known,
but decreased glucose metabolism was reported in the anterior
and posterior cingulate gyri in normal adults with dream
enactment behaviors.34 These ﬁndings point out a possible link
to DLB given that the temporal cortex and posterior cingulate are
known to be metabolically deﬁcient in DLB.
It is helpful to discuss several issues for the study looking into
clinical correlation with regional glucose metabolism. Although
RBD duration and EMG chin activity represent clinically related
indices, these two variables were not correlated in our RBD cohort.
The regression analysis showed similar and different clinical
correlates between these two variables on a regional basis.
However, the correlations were moderate overall with only
one region survived after correction for the effect of multiple
comparisons. These results were likely because of the relatively
short duration, narrow range of chin muscle activity, and limited
sample size in our RBD patients. Whether our ﬁndings could be
reproduced still need to be explored further in a large sample with
a longer disease duration and wider distribution in muscle activity
on an individual level. Nonetheless, these imaging results showed
that RBD duration and EMG chin activity are partially overlapping,
but they may also serve as different descriptors for assessing
unique features of RBD.
Metabolic Alterations and Markers of α-Synucleinpathy
RBD is considered to represent a clinical risk marker for the
subsequent development of α-synuclein diseases, especially for
PD and DLB.2 Regional metabolic abnormality in PD has been
reported in several independent cohorts, and was characterized
by hypermetabolism in the basal ganglia, sensorimotor areas,
pons, and cerebellar cortices, associated with hypometabolism in
the parieto-occipital and prefrontal cortices.12–14 Although the
cortical metabolism showed a few similarities between PD and
RBD based on the result reported in this study, it is worth noting
that pontine hyperactivity acted as a key metabolic feature in both
disorders. This ﬁnding was in accordance with the hypothesis of
Braak staging,35 which described the ﬁrst appearance of Lewy
bodies in the pontine tegmentum in PD, associated with
subsequent attainment of other cerebral regions as disease
evolved. Further support was provided by increased metabolic
activity and perfusion of local pons in patients with RBD,
with greater perfusion in the patients who later phenoconverted
to PD/DLB in comparison with their nonphenoconverter counterparts.10,24 Metabolic studies in DLB also shared some ﬁndings with
the current study, such as hypometabolism in the occipital areas.
This region, which is specialized in color vision, might explain the
dysfunction of color discrimination observed in both patients with
RBD36 and those with DLB.37
Comparison with Other Studies and Methodological Issues
Using the same set of imaging data used in the present study, we
have recently described an RBD-related covariance pattern
(RBDRP) characterized by increased metabolic activity in the pons,
thalamus, medial frontal and sensorimotor areas, hippocampus,
supramarginal and inferior temporal gyri, and posterior cerebellum, associated with decreased activity in occipital and
superior temporal regions.19 This pattern presented a high
degree of overlap to the analogous PD-related covariance
pattern.17 In addition, network expression of RBDRP discriminated
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individual patients from healthy controls and revealed a possible
evolution process from this disorder on the way to the
development of PD.
Although we observed high similarities between the topography of RBDRP in the previous study and the distribution of
RBD-related regional metabolic activities in the current study, it is
important to note that these results portray very different
measures of brain function. Indeed, the prior study concerned
the derivation of a brain network using spatial covariance analysis
of variance information of glucose metabolism measured in FDG
PET images. By contrast, the current study reported the regionally
speciﬁc differences in mean value of glucose metabolism using
SPM. It has been shown that the expression of a brain network can
be measured prospectively in new subjects for group classiﬁcation
on an individual case basis and the network approach has a higher
sensitivity compared with SPM in detecting localized changes in
neurodegenerative disorders.38 The latter is supported by the fact
that metabolic changes observed in some regions such as the
thalamus in the RBDRP were absent in the present study.
Nevertheless, the ﬁndings from the current study provided
complementary information to the previous study and helped
support and explain the elevated RBDRP activity in the RBD
subjects as a group.19 In general, the higher the similarity between
the regional metabolic abnormality in a single patient and the
topography of a brain network, the greater the subject score of
that brain network in the single patient.
It is necessary to understand the discrepancies between this
work and other studies in light of some variations and limitations
inherent in the experiment. The major factor may be attributed to
the differences in patient samples and imaging methodology.
Indeed, the recent study with FDG PET measured brain metabolic
changes in a set of predeﬁned regions in a smaller number of
patients with similar RBD duration,10 whereas the other studies
used SPECT imaging to measure brain perfusion in a comparable
number of patients with longer RBD duration.10,11,24 Although
perfusion SPECT and metabolic PET are supposed to measure the
same neural activity in healthy brains, CBF and glucose
metabolism may differ from each other under diseased conditions,
particularly after medications acting on the central nervous
systems.16 Moreover, only relative values of CBF or metabolism
were quantiﬁed in all these studies owing to clinical constraints,
although there might be more statistic power if absolute CBF or
metabolism was calculated with the collection of arterial blood
sampling.39–40
We also need to point out that brain metabolism of our RBD
patients was measured with FDG PET in wake state but not in REM
stage, such as in the previous metabolic or perfusion imaging
studies. It was conceivable that assessment of metabolic activity in
REM sleep might provide different results. To our surprise, we
found that most areas with signiﬁcant metabolic alterations in
waking patients were also associated with eye movements in
healthy controls during REM sleep.39 Similarly, a CBF study with
PET also observed signiﬁcant changes in the activity of limbic and
paralimbic areas (e.g., the hippocampus/parahippocampal gyrus,
cingulate, insula, and temporal pole) in healthy subjects in the
REM stage.40 Although the potential function of limbic/paralimbic
activation during REM sleep remains unclear, it is phenomenologically consistent with the autonomic activation and
lability observed in this particular stage, and could be related to
the rich emotional content of dreams reported during this sleep
stage.40 The accordant ﬁndings from the present and other
studies of waking RBD patients or healthy subjects in REM sleep
provided further support that the regions with metabolic
abnormalities we observed in relation to RBD did not occur by
chance.
Journal of Cerebral Blood Flow & Metabolism (2015), 2062 – 2069

CONCLUSION
In this study, we substantiated the distribution of characteristic
regional metabolic activity in RBD using FDG PET imaging and
voxel-based brain mapping analysis. We also found signiﬁcant
correlations between abnormal metabolic values and different
clinical indices of RBD duration and chin EMG activity. The
abnormal metabolic substrates provided further support in light of
RBD as a risk factor for developing neurodegenerative parkinsonism. Because of preliminary nature of the current work at baseline,
cross-sectional studies in other independent cohorts with larger
sample sizes would be necessary to conﬁrm the reproducibility of
abnormal RBD-related regional metabolic activities and their
clinical correlates. Furthermore, follow-up studies would also be
carried out in our patient cohort to clarify the relationships
between metabolic activities and their longitudinal changes in
disease progression and eventual clinical outcomes of RBD
patients.
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